Rethinking How Medicines Are Discovered
Unlocking Nature’s Therapeutic Potential Through Rigorous Pharmaceutical Science
Much of modern pharmaceutical innovation has focused on developing medicines that act on individual biological targets. Increasingly, scientific research recognises that many chronic and complex diseases involve multiple interconnected biological pathways.
Pet Pharma Holdings is developing a new class of veterinary prescription medicines using proprietary artificial intelligence and phytopharmaceutical science.
Our PolyNexis+™ discovery platform identifies novel multi-compound therapeutic formulations designed to address major unmet needs in companion animal healthcare.
$
0
b
Global pet care market in 2022
$
0
b
Global pet care market by 2030
0
m+
Dogs and cats globally
Pet Pharmaceuticals is pioneering a different approach to discovering and developing prescription medicines.
We are pioneering a new therapeutic class of pharmaceutical-grade multi-pathway combination phytopharmaceutical medicines, bringing together nature’s therapeutic diversity with rigorous pharmaceutical science to develop differentiated prescription medicines designed to address important unmet clinical needs in companion animal health.
Our ambition is simple:
To create safer, more effective medicines for chronic and complex diseases by addressing the biological complexity of disease rather than individual biological targets.
To create safer, more effective medicines for chronic and complex diseases by addressing the biological complexity of disease rather than individual biological targets.
Unlocking an Untapped Scientific Opportunity
Nature contains an extraordinary diversity of bioactive compounds. Yet much of this therapeutic potential has remained underdeveloped within modern pharmaceutical medicine because of the scientific, analytical and development challenges involved in identifying, standardising and combining complex natural-product candidates.
Pet Pharmaceuticals is building the scientific capability required to unlock this opportunity. By integrating natural-product science, pharmaceutical development, proprietary scientific knowledge and advanced analytical technologies, we aim to transform promising biological activity into consistent, validated and commercially relevant prescription medicines.
Why Better Medicines Are Needed
Many chronic and complex diseases remain difficult to treat effectively. Existing medicines may address only part of the underlying disease biology, produce significant side effects, lose effectiveness over time or prove unsuitable for long-term use.
Our approach is designed to address disease through multiple complementary biological pathways. This creates the potential for broader therapeutic activity, improved tolerability and differentiated medicines capable of addressing important limitations in current standards of care.
Our Integrated Scientific Discovery Capability
Innovation at Pet Pharmaceuticals is driven by our Integrated Scientific Discovery Capability: a repeatable scientific engine combining pharmaceutical science, natural-product research, proprietary knowledge, advanced analytics and disciplined development processes.
Within this capability, our proprietary PolyNexis+™ Discovery Platform supports candidate identification, optimisation and scientific decision-making. AI and advanced data science act as enabling technologies within this process, strengthening discovery while remaining one component of the broader scientific capability.
PolyNexis+™ transforms nature’s potential into pharmaceutical reality.
Our Initial Therapeutic Portfolio
Our initial portfolio addresses six important disease areas in companion animal health:
Parasiticides
Osteoarthritis
Dermatitis
Oncology (Lymphoma)
Diabetes / Obesity
Anxiety
Together, these programmes demonstrate the breadth and scalability of our scientific capability while creating multiple opportunities for future development, strategic partnership and value creation.
Scientific Milestones
The lead Parasiticide Programme has completed in vitro efficacy studies, representing an important early scientific milestone. The resulting data will inform the next stage of development and support the disciplined progression of the programme through preclinical validation.
Across the wider portfolio, programmes are being advanced through a stage-gated process designed to prioritise the strongest scientific opportunities, manage capital efficiently and generate partner-ready evidence.
Why Pet Pharmaceuticals
- A new therapeutic class designed for chronic and complex disease.
- A repeatable Integrated Scientific Discovery Capability.
- A diversified portfolio across six high-value therapeutic indications.
- A capital-efficient model focused on discovery, development, validation and monetisation.
- A world-class Board supported by an internationally recognised Scientific & Strategic Advisory Board.
- A growing competitive moat built through the integration of scientific capability, proprietary nucleus product combinations, protected scientific sources and knowledge, and expanding intellectual property.
Why Pet Pharma?
The global veterinary healthcare industry is undergoing profound change.
Pet owners increasingly expect human-grade healthcare for their animals, while veterinary pharmaceutical companies face growing challenges including:
Resistance to existing therapies
Increasing regulatory scrutiny
Limited therapeutic innovation
Demand for safer and more sustainable medicines
Pet Pharmaceuticals is addressing these challenges through the development of clinically validated, prescription phytopharmaceuticals supported by artificial intelligence.
Introducing PolyNexis+™
Our Proprietary AI Discovery Platform
PolyNexis+™ combines:
- Artificial Intelligence
- Phytochemical Science
- Drug Development Expertise
- Predictive Modelling
- Regulatory Data Management
The platform enables:
Rapid Identification of Novel Compounds
Synergistic Formulation Design
Predictive Safety Assessment
Accelerated Development Pathways
Creation of Multiple Therapeutic Products From a Single Platform
Companion Animals Today. Broader Opportunities Tomorrow.
Our immediate priority is companion animal medicine, where significant unmet clinical needs, attractive development timelines and strong commercial dynamics provide an exceptional opportunity to create value.
Over time, the scientific capability and therapeutic knowledge being developed may support opportunities in livestock health and selected human therapeutic applications, consistent with the wider principles of One Health.
Market Opportunity
Pet Pharmaceuticals sits at the intersection of several of the fastest-growing sectors in global animal health.